23.08.2017

AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial (LipP 1) with Topical Pritelivir for the Treatment of recurrent Labial Herpes
The final patient has been treated in the clinical phase 2 efficacy and safety study LipP 1 evaluating topical pritelivir, a small molecule helicase-primase inhibitor, for the treatment of recurrent labial herpes (cold sores)

more ...

01.08.2017

AiCuris Granted Fast Track Designation by U.S. FDA for Oral Pritelivir for Treatment of HSV Infections in Immunocompromised Adults
Fast track is a process designed to facilitate the development, expedite the review and accelerate the approval process of drugs to treat serious conditions and fill an unmet medical need, with the purpose of getting important new drugs to patients sooner

more ...

09.05.2017

AiCuris Initiates U.S. Clinical Phase 2 Trial with Oral Pritelivir
Opening of the first site in its clinical phase 2 study, PRIOH-1

more ...

08.03.2017

AiCuris selects Mercachem as preferred medicinal chemistry partner

more ...

17.01.2017

AiCuris Announces Publication of Phase 2 Clinical Trial Results of Investigational Anti-Herpes Simplex Virus Agent Pritelivir in JAMA
Study results clearly supported pritelivir to be more effective than alacyclovir for suppression of herpes simplex virus (HSV) genital shedding in patients with frequent recurrences

more ...

04.01.2017

AiCuris Initiates Clinical Development of AIC499, a Novel Resistance-Breaking Antibiotic against a Broad Range of MDR Gram-Negative Bacteria
Program supported by the Innovative Medicines Initiative

more ...